Karen Firestone

Director Karen Firestone buys 3.8K shares of AMLX at $13.51; stock now down 30.0% from 52-week high, company unprofitable with $-41.3M net income

Karen Firestone purchased 3,800 shares at $13.51 on 2026-05-21, increasing her holdings by 6.0% to 66,900 shares total. The purchase occurs as AMLX trades at $13.01, down 30.0% from its 52-week high of $18.60 and down 11.7% over the past 30 days. Notably, Firestone's prior two purchases at AMLX (2025-12-23 and 2024-09-05) both showed positive 90-day returns of 30.4% and 146.7% respectively, establishing a pattern of well-timed entries at this ticker. However, the company's fundamentals present significant headwinds: latest quarterly revenue is $0.00, full-year net income was $-41.3M, and annual revenue growth declined 100.0% year-over-year, indicating an unprofitable business in significant financial distress.

Director Karen Firestone bought 8,100 shares of AMLX at $12.45 on 2025-12-23, now valued 22% below 52-week high amid -77.1% revenue decline.

Karen Firestone, a Director at Amylyx Pharmaceuticals, purchased 8,100 shares at $12.45, adding to her position (now 63,100 shares post-transaction) during a period of significant stock weakness: the current price of $12.31 is -22.0% from the 52-week high and down 30-day change: -16.1%. The company faces severe operational headwinds—annual revenue growth has contracted by -77.1% year-over-year, net income was $-34,386,000.00 for the latest period, and quarterly revenue stands at $0.00, signaling a critical challenge in commercialization or market demand. Firestone's cross-ticker track record shows her prior open-market buys generated strong returns (avg 90d return +146.7%, 100.00% win rate), though her same-ticker history at AMLX includes only one measurable prior buy (2024-09-05, which returned +146.7% over 90 days); this current purchase occurs as the stock has declined materially from recent highs. The buy is discretionary and open-market, distinct from any scheduled trading plan, and occurs in the context of deteriorating fundamentals and ongoing stock weakness.

Director Karen Firestone buys 50,000 shares of AMLX at $2.13; stock down 88.1% from 52-week high.

Firestone purchased 50,000 shares at $2.13 on 2024-09-05, increasing her holdings to 55,000 shares from 5,000 shares. The stock now trades at $2.52, down 88.1% from the 52-week high of $21.19. Amylyx Pharmaceuticals is unprofitable with net income of $-72,700,000.00 in the latest quarter, though it reported annual revenue growth of +1612.9% year-over-year. Her prior open-market buy at this ticker showed a 90-day return of -78.8%, indicating a pattern of unfavorable timing outcomes. This buy occurred near a relative local bottom (stock has rebounded +44.8% over the past 90 days), but without scheduled trading plan disclosure, the context for this discretionary purchase—amid massive losses and a collapsed valuation—remains unclear.